NCNA vs. TRVN, BFRI, CVKD, VIRI, BNOX, CYCN, VCNX, EFTR, GRAY, and HEPA
Should you be buying NuCana stock or one of its competitors? The main competitors of NuCana include Trevena (TRVN), Biofrontera (BFRI), Cadrenal Therapeutics (CVKD), Virios Therapeutics (VIRI), Bionomics (BNOX), Cyclerion Therapeutics (CYCN), Vaccinex (VCNX), eFFECTOR Therapeutics (EFTR), Graybug Vision (GRAY), and Hepion Pharmaceuticals (HEPA). These companies are all part of the "pharmaceutical preparations" industry.
NuCana (NASDAQ:NCNA) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, community ranking, analyst recommendations and profitability.
44.0% of NuCana shares are held by institutional investors. Comparatively, 13.6% of Trevena shares are held by institutional investors. 31.2% of NuCana shares are held by company insiders. Comparatively, 2.4% of Trevena shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Trevena had 1 more articles in the media than NuCana. MarketBeat recorded 3 mentions for Trevena and 2 mentions for NuCana. Trevena's average media sentiment score of 0.71 beat NuCana's score of 0.43 indicating that Trevena is being referred to more favorably in the news media.
NuCana has higher earnings, but lower revenue than Trevena. NuCana is trading at a lower price-to-earnings ratio than Trevena, indicating that it is currently the more affordable of the two stocks.
NuCana currently has a consensus target price of $125.00, indicating a potential upside of 3,206.88%. Trevena has a consensus target price of $9.00, indicating a potential upside of 2,063.46%. Given NuCana's higher probable upside, research analysts clearly believe NuCana is more favorable than Trevena.
NuCana's return on equity of -115.42% beat Trevena's return on equity.
NuCana has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500. Comparatively, Trevena has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500.
Trevena received 367 more outperform votes than NuCana when rated by MarketBeat users. Likewise, 72.01% of users gave Trevena an outperform vote while only 67.57% of users gave NuCana an outperform vote.
Summary
Trevena beats NuCana on 8 of the 15 factors compared between the two stocks.
Get NuCana News Delivered to You Automatically
Sign up to receive the latest news and ratings for NCNA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NCNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
